Should I buy or sell Theratechnologies stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Theratechnologies in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" TH shares. View TH analyst ratings or view top-rated stocks .

What is Theratechnologies' stock price target for 2024?

2 Wall Street research analysts have issued 1 year target prices for Theratechnologies' stock. Their TH share price targets range from C$5.50 to C$5.50. On average, they expect the company's stock price to reach C$5.50 in the next twelve months. This suggests a possible upside of 205.6% from the stock's current price. View analysts price targets for TH or view top-rated stocks among Wall Street analysts .

How have TH shares performed in 2024?

Theratechnologies' stock was trading at C$2.14 at the beginning of the year. Since then, TH stock has decreased by 15.9% and is now trading at C$1.80. View the best growth stocks for 2024 here .

When is Theratechnologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 10th 2024. View our TH earnings forecast .

How were Theratechnologies' earnings last quarter?

Theratechnologies Inc. (TSE:TH) posted its quarterly earnings data on Wednesday, February, 21st. The company reported ($0.11) earnings per share for the quarter. The company had revenue of $31.93 million for the quarter. Theratechnologies had a negative trailing twelve-month return on equity of 1,116.86% and a negative net margin of 29.30%.

What other stocks do shareholders of Theratechnologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Theratechnologies investors own include Stars Group (TSGI) , BCE (BCE) , ProMetic Life Sciences (PLI) , Teranga Gold (TGZ) , Nemaska Lithium (NMX) , Shopify (SHOP) , United Therapeutics (UTHR) and Avigilon (AVO) .

How do I buy shares of Theratechnologies?

Shares of TH stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor , Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. Compare Top Brokerages Here .

TSE:TH

Theratechnologies (TH) Stock Price, News & Analysis

→ Nerd Investor Reveals Secret To Make Money With A.I. (From InvestorPlace) (Ad)

Free TH Stock Alerts

C$1.80

-0.09 (-4.76%)

(As of 04/15/2024 ET)

Compare

Today's Range: C$1.80
▼
C$1.92
50-Day Range: C$1.64
▼
C$2.29
52-Week Range: C$1.22
▼
C$5.84

Volume: 38,323 shs
Average Volume: 40,535 shs
Market Capitalization: C$82.76 million

P/E Ratio: N/A
Dividend Yield: 3.76%
Price Target: C$5.50

Stock Analysis Analyst Forecasts Chart Competitors Earnings Headlines Insider Trades

Get Theratechnologies alerts:

Theratechnologies MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 205.6% Upside
C$5.50 Price Target
Short Interest: N/A
Dividend Strength: Weak
Based on Four Factors
Sustainability: N/A
News Sentiment: 0.45
Based on 8 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.41 out of 5 stars

3.3

Analyst's Opinion

Consensus Rating
Theratechnologies has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Theratechnologies has received no research coverage in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for TH.

1.7

Dividend Strength

Dividend Leadership
Theratechnologies is a leading dividend payer. It pays a dividend yield of 3.76%, putting its dividend yield in the top 25% of dividend-paying stocks.
Dividend Growth
Theratechnologies does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TH.

2.5

News and Social Media Coverage

News Sentiment
Theratechnologies has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 8 news articles for Theratechnologies this week, compared to 1 article on an average week.
Search Interest
2 people have searched for TH on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Theratechnologies insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 6.29% of the stock of Theratechnologies is held by insiders.
Percentage Held by Institutions
50.88% of the stock of Theratechnologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Theratechnologies is -1.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Theratechnologies is -1.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Growth Ratio
Due to a projected decrease in earnings for Theratechnologies, their PEG ratio cannot be calculated.

See Top Rated MarketRank™ Stocks Here

Ad TradeSmith

A.I. Pioneer Issues Urgent Warning to Americans

With artificial intelligence creeping into every facet of our lives, what should you be doing to "A.I.-Proof" your future? It's the question on many of our minds.

Click here to see Louis' new video for yourself.

About Theratechnologies Stock (TSE:TH)

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

TH Stock Price History

30 days | 90 days | 365 days | Advanced Chart

TH Stock News Headlines

April 15, 2024 | americanbankingnews.com

FY2024 EPS Estimates for Theratechnologies Inc. (TSE:TH) Raised by Analyst

April 14, 2024 | theglobeandmail.com

Theratechnologies: Top 10 Undervalued Biotechnology Industry Stocks (TH)

April 16, 2024 | InvestorPlace (Ad)

Forget Nvidia, buy this A.I. Stock Now

Forget Nvidia, Microsoft or Google. Our tech expert and venture capitalist Luke Lango believes this is Elon Musk’s favorite A.I. stock. Why? Because this company is supplying Elon Musk with a key piece of advanced tech for his new A.I. venture.

April 12, 2024 | americanbankingnews.com

Theratechnologies (TSE:TH) Share Price Passes Above 50-Day Moving Average of $2.01

April 10, 2024 | msn.com

U.S. Index Futures Show Mixed Trend Ahead of Key Inflation Data Release, Oil Prices Edge Higher

April 9, 2024 | stockhouse.com

Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology(TM) Oncology Platform

April 8, 2024 | americanbankingnews.com

Theratechnologies (TH) Set to Announce Earnings on Wednesday

March 11, 2024 | msn.com

Nurse-Led Strategy Reduces Cardiovascular Risk Factors for People With HIV

April 16, 2024 | InvestorPlace (Ad)

Forget Nvidia, buy this A.I. Stock Now

February 27, 2024 | morningstar.com

Theratechnologies Shares Sink Premarket After FDA Refusal to File Letter

February 27, 2024 | seekingalpha.com

Theratechnologies stock plunges after FDA denies review of Trogarzo sBLA

February 23, 2024 | finance.yahoo.com

Theratechnologies Full Year 2023 Earnings: Misses Expectations

February 21, 2024 | finance.yahoo.com

Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2023 and Provides 2024 Guidance

February 21, 2024 | markets.businessinsider.com

Here's what Wall Street expects from Theratechnologies's earnings report

February 20, 2024 | benzinga.com

7THTX : Theratechnologies Earnings Preview

February 20, 2024 | finance.yahoo.com

Theratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel Zendusortide (TH1902) Molecular Mechanism of Action

February 6, 2024 | finance.yahoo.com

Theratechnologies to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update

January 31, 2024 | finance.yahoo.com

Positive Signs As Multiple Insiders Buy Theratechnologies Stock

January 25, 2024 | msn.com

FDA denies approval for Theratechnologies’ tesamorelin F8

January 24, 2024 | marketwatch.com

Theratechnologies: FDA Rejects Newer Egrifta Formulation

January 24, 2024 | marketwatch.com

Theratechnologies Shares Slide Premarket as FDA Turns Away Newer Egrifta

January 24, 2024 | markets.businessinsider.com

Theratechnologies Stock Falls On CRL From FDA For F8 Formulation Of Tesamorelin

January 24, 2024 | marketwatch.com

Theratechnologies Shares Sink at Open After FDA Rejects Newer Tesamorelin Formulation

January 24, 2024 | finance.yahoo.com

Theratechnologies Receives Complete Response Letter (CRL) from the FDA for the F8 Formulation of Tesamorelin sBLA

January 23, 2024 | marketwatch.com

Theratechnologies Shares Fall as FDA Continues to Review License Application for Tesamorelin

January 23, 2024 | msn.com

Theratechnologies stock slides as Egrifta review runs beyond FDA target date

January 23, 2024 | markets.businessinsider.com

Theratechnologies Says FDA Needs More Time To Decide On Tesamorelin F8 SBLA

See More Headlines

Receive TH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Theratechnologies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/21/2024
Today: 4/15/2024
Next Earnings (Estimated): 7/10/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: TSE
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: TSE:TH
CUSIP: N/A
CIK: N/A
Web: www.theratech.com
Phone: +1-514-3367800
Fax: N/A
Employees: 103
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: C$5.50
High Stock Price Target: C$5.50
Low Stock Price Target: C$5.50
Potential Upside/Downside: +205.6%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): C($1.24)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 48.99
P/E Growth: -8.5
Net Income: C$-23,960,000.00
Net Margins: -29.30%
Pretax Margin: N/A
Return on Equity: -1,116.86%
Return on Assets: -6.33%

Debt

Debt-to-Equity Ratio: 562.07
Current Ratio: 1.34
Quick Ratio: 0.64

Sales & Book Value

Annual Sales: C$81.76 million
Price / Sales: 1.01
Cash Flow: C$0.48 per share
Price / Cash Flow: 3.76
Book Value: C($0.45) per share
Price / Book: -4.00

Miscellaneous

Outstanding Shares: 45,980,000
Free Float: N/A
Market Cap: C$82.76 million
Optionable: Not Optionable
Beta: 1.73

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Mr. Paul Lévesque (Age 59)
President, CEO & Director
Comp: $1.6M
Mr. Philippe Dubuc M.B.A. (Age 57)
MBA, Senior VP & CFO
Comp: $587.17k
Mr. Jocelyn Lafond L.L.M. (Age 56)
LL.B., General Counsel & Corporate Secretary
Comp: $429.6k
Dr. Christian Marsolais Ph.D. (Age 61)
Senior VP & Chief Medical Officer
Comp: $590.29k
Mr. John Leasure (Age 59)
Global Commercial Officer
Comp: $571.68k
Hon. Andre Dupras M.Sc. (Age 60)
Vice President of Human Resources

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

TH Stock Analysis - Frequently Asked Questions

Should I buy or sell Theratechnologies stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Theratechnologies in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" TH shares.
View TH analyst ratings or view top-rated stocks.
What is Theratechnologies' stock price target for 2024?: 2 Wall Street research analysts have issued 1 year target prices for Theratechnologies' stock. Their TH share price targets range from C$5.50 to C$5.50. On average, they expect the company's stock price to reach C$5.50 in the next twelve months. This suggests a possible upside of 205.6% from the stock's current price.
View analysts price targets for TH or view top-rated stocks among Wall Street analysts.
How have TH shares performed in 2024?: Theratechnologies' stock was trading at C$2.14 at the beginning of the year. Since then, TH stock has decreased by 15.9% and is now trading at C$1.80.
View the best growth stocks for 2024 here.
When is Theratechnologies' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 10th 2024.
View our TH earnings forecast.

How were Theratechnologies' earnings last quarter?: Theratechnologies Inc. (TSE:TH) posted its quarterly earnings data on Wednesday, February, 21st. The company reported ($0.11) earnings per share for the quarter. The company had revenue of $31.93 million for the quarter. Theratechnologies had a negative trailing twelve-month return on equity of 1,116.86% and a negative net margin of 29.30%.
What other stocks do shareholders of Theratechnologies own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Theratechnologies investors own include Stars Group (TSGI), BCE (BCE), ProMetic Life Sciences (PLI), Teranga Gold (TGZ), Nemaska Lithium (NMX), Shopify (SHOP), United Therapeutics (UTHR) and Avigilon (AVO).
How do I buy shares of Theratechnologies?: Shares of TH stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

This page (TSE:TH) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Theratechnologies (TH) Stock Price, News & Analysis

Theratechnologies MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

Company Ownership

Earnings and Valuation

About Theratechnologies Stock (TSE:TH)

TH Stock Price History

TH Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders

TH Stock Analysis - Frequently Asked Questions

Overall MarketRank^™